title: A Prognostic Analysis of Male Breast Cancer (MBC) Compared with Post-Menopausal Female Breast Cancer (FBC).
abstract: BACKGROUND
  Male breast cancer (MBC) is known to be rare compared with female breast cancer (FBC) and to account for only 1% of all breast cancers. To date, male patients diagnosed with breast cancer are normally treated based on the guidelines for FBC. Specifically, studies have found that diagnosing and treating MBC patients under the guidelines for the treatment of post-menopausal FBC are more favorable than are those of pre/peri-menopausal FBC from a physiological perspective because MBC and post-menopausal FBC patients show high estrogen receptor (ER) expression in the tumor and low estrogen expression in the body. In this medical study, we aimed to examine whether MBC actually has the same prognosis as post-menopausal FBC.
  
  
  METHODS
  We identified MBC patients who were diagnosed as operable and who completed clinical treatment and we used follow-up data that were collected from January 2001 to January 2011. Each MBC patient was paired with four FBC patients who were diagnosed within the same period (two were pre/peri-menopausal, and two were post-menopausal). We compared disease-free survival (DFS) and overall survival (OS) among three groups, i.e., pre/peri-menopausal FBC (group A), post-menopausal FBC (group B) and MBC (group M), using the Kaplan-Meier method and a Cox proportional hazards regression model. We also evaluated the clinical characteristics of breast cancer patients using t-tests and chi-square tests. We used ten consecutive years of data that were collected at Zhejiang Provincial Cancer Hospital.
  
  
  RESULTS
  We identified 91 MBC cases for group M, 182 FBC cases for group A and 182 FBC cases for group B. The median follow-up period was 112 months. MBC cases were much more frequently ER positive than those of group A and group B (p<0.01); a similar trend was also found for progesterone (PR)-positive cases (p<0.01). The MBC group showed much lower human epidermal growth factor receptor-2 (HER2) expression than did the other groups (p<0.01). The 10-year OS rates were 79.1% for group M (72/91), 79.1% (144/182) for group A, and 87.9% (160/182) for group B, log-rank test indicated that group M had similar mean OS time as group A and group B (GourpM vs group A: p = 0.709; group M vs group B: p = 0.042). The Cox proportional hazards regression model indicated that pre/peri-menopausal FBC had similar DFS (hazard ratio (HR) = 0.706, p = 0.262) and OS (HR = 1.029, p = 0.941) values compared with MBC, whereas post-menopausal FBC had higher DFS (HR = 0.454, p = 0.004) and OS (HR = 0.353, p = 0.003) values than did MBC.
  
  
  CONCLUSIONS
  Based on this study, we can conclude that MBC displayed higher ER- and PR-positive expression and lower HER2-positive expression than both post-menopausal and pre/peri-menopausal FBC. However, the DFS and OS values of MBC were similar to those of pre/peri-menopausal FBC and were worse than were those of post-menopausal FBC.
authors: Department of Breast Tumor Surgery, Zhejiang Provincial Cancer Hospital, Hangzhou, Zhejiang Province, P.R. China.
authors: Xing-Fei
authors: XF
authors: Yu
authors: Department of Breast Tumor Surgery, Zhejiang Provincial Cancer Hospital, Hangzhou, Zhejiang Province, P.R. China.
authors: Hong-Jian
authors: HJ
authors: Yang
authors: Department of Breast Tumor Surgery, Zhejiang Provincial Cancer Hospital, Hangzhou, Zhejiang Province, P.R. China.
authors: Yang
authors: Y
authors: Yu
authors: Department of Breast Tumor Surgery, Zhejiang Provincial Cancer Hospital, Hangzhou, Zhejiang Province, P.R. China.
authors: De-Hong
authors: DH
authors: Zou
authors: Department of Medical Oncology, Zhejiang Provincial Cancer Hospital, Hangzhou, Zhejiang Province, P.R. China.
authors: Lu-Lu
authors: LL
authors: Miao
mesh_terms: D000328:Adult; D000368:Aged; D018567:Breast Neoplasms, Male / Q000175:diagnosis / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D017698:Postmenopause; D016016:Proportional Hazards Models; D015996:Survival Rate